FutureFemHealth

FutureFemHealth

Home
Work with us / Advertise
CensHERship
FutureFemHealth Pro
Partners and contributors
Archive
About
💌 Issue 161: $35m for preeclampsia | new heart attack guidance | Flo’s IPO signal | birth injury investment
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
Phira emerges from stealth with earring wearable to track hormone patterns
The US startup is using physiological signals from behind the ear to follow changes associated with estrogen, LH and progesterone across the menstrual…
 • Anna O'Sullivan
Flo Health hires IPO-experienced CMO as it enters next phase of growth
Rina Hahn helped scale Remitly through its IPO, experience Flo says demonstrates the capabilities it needs for its next phase.
 • Anna O'Sullivan
Is maternal birth injury prevention becoming an investable category?
New funding for Peripear and Materna Medical suggests investors are looking upstream at a common but overlooked problem.
 • Anna O'Sullivan
UK birth injury prevention startup PeriPear secures £1.2m in equity and grant funding
PeriPear is developing a wearable device designed to help prevent tearing during vaginal birth.
 • Anna O'Sullivan

August 2026

Amara Therapeutics completes recruitment of nearly 600 women in major overactive bladder trial
A 596-patient randomized trial will test whether an app-based treatment can improve overactive bladder symptoms and quality of life in women.
 • Anna O'Sullivan
What 2,000 pitch decks tell us about women’s health investing
Cross-Border Impact Ventures’ Annie Thériault on five years inside the women’s health investment pipeline.
 • Anna O'Sullivan
One year on: Jason Clark on what Women’s Health Horizons has learned — and what the sector needs next
FutureFemHealth caught up with the founder and CEO of Women’s Health Horizons
 • Anna O'Sullivan
💌 Issue 160: $30m for heavy menstrual bleeding | Rael PE investment | $284m period care deal | HPV home testing
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
Reimbursement has moved up the women’s health agenda. Here’s why.
Founders and investors are thinking about who pays much earlier.
 • Anna O'Sullivan
Women’s health companies urged to weigh in on US Medicare payment changes
Advocates say the industry needs to make its voice heard
 • Anna O'Sullivan
Channel Medsystems raises $30m to expand heavy menstrual bleeding treatment
US medtech will accelerate commercial rollout of its non-hormonal Cerene treatment
 • Anna O'Sullivan
© 2026 FutureFemHealth Ltd · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture